Search results for " outcome assessment"

showing 10 items of 59 documents

Clinical Severity in Different Waves of SARS-CoV-2 Infection in Sicily: A Model of Smith’s “Law of Declining Virulence” from Real-World Data

2022

Background: The COVID-19 epidemic had a rapid spread worldwide with a continuous and fast mutation of the virus, resulting in the emergence of several variants of concern (VOC). The aim of this study was to evaluate the severity of each VOC among SARS-CoV-2 infected subjects by investigating deaths, ICU admissions, intubations, and severe critical symptoms. Methods: An ecological observational study was performed to evaluate mortality rates and clinical characteristics of 321,490 unvaccinated Sicilian SARS-CoV-2 cases observed from 2 March 2020 to 27 March 2022. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by multivariate logistic regression analysis evaluating factors…

Infectious DiseasesVirologyclinical outcomes COVID-19 epidemiology health care outcome assessment public health SARS-CoV-2
researchProduct

The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.

2017

Background and aims The psychometric hepatic encephalopathy score (PHES) is the “gold standard” for minimal hepatic encephalopathy (MHE) diagnosis. Some reports suggest that some cirrhotic patients “without” MHE according to PHES show neurological deficits and other reports that neurological alterations are not homogeneous in all cirrhotic patients. This work aimed to assess whether: 1) a relevant proportion of cirrhotic patients show neurological deficits not detected by PHES; 2) cirrhotic patients with mild neurological deficits are a homogeneous population or may be classified in sub-groups according to specific deficits. Methods Cirrhotic patients “without” (n = 56) or “with” MHE (n = 4…

Liver CirrhosisMalePathologyPediatricsCirrhosisPsychometricsSocial Scienceslcsh:MedicineNeuropsychological Tests0302 clinical medicineMedicine and Health SciencesPsychologyCluster AnalysisAttentionlcsh:ScienceHepatic encephalopathyCognitive Impairmenteducation.field_of_studyMultidisciplinaryCognitive NeurologyLiver DiseasesMiddle AgedNeurologyCirrhosisOncologyFemale030211 gastroenterology & hepatologyResearch Articlemedicine.medical_specialtyPsychometricsCognitive NeurosciencePopulationGastroenterology and HepatologyCarcinomas03 medical and health sciencesNeuropsychologyGastrointestinal TumorsmedicineHumanseducationNeuropsychological TestingAgedWorking memorybusiness.industryGold standardlcsh:RCognitive PsychologyCase-control studyBiology and Life SciencesCancers and NeoplasmsReproducibility of ResultsHepatocellular Carcinomamedicine.diseasePatient Outcome AssessmentCase-Control StudiesHepatic EncephalopathyStroop TestCognitive Sciencelcsh:QbusinessPsychomotor Performance030217 neurology & neurosurgeryNeuroscienceFollow-Up StudiesStroop effectPLoS ONE
researchProduct

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes

2021

Survival in high-risk neuroblastoma (HR-NB) patients remains poor despite multimodal treatment. We aimed to identify HR-NB patients with worse outcomes by analyzing the genomic instability derived from segmental chromosomal aberrations. We calculated 3 genomic instability indexes for primary tumor SNP array profiles from 127 HR-NB patients: (1) Copy number aberration burden (%gainslength+%losseslength), (2) copy number load (CNL) (%gainslength-%losseslength) and (3) net genomic load (NGL) (%gainsamount-%lossesamount). Tumors were classified according to positive or negative CNL and NGL genomic subtypes. The impact of the genomic instability indexes on overall survival (OS) was assessed with…

Male0301 basic medicineGenome instabilityOncologyCancer ResearchCopy number loadSNPa single nucleotide polymorphism arrayNeuroblastoma0302 clinical medicineHigh risk neuroblastomaSegmental chromosomal aberrationsHR high-riskCNA copy number aberrationTumor biologyCNL copy number loaddNGL decreased net genomic loadlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumornCNL negative copy number loadGI genomic instabilityHomogeneous030220 oncology & carcinogenesisMNA MYCN-amplificationFemaleHR-NB high-risk neuroblastomaNB neuroblastomaSNP arrayOriginal articlemedicine.medical_specialtyDNA Copy Number VariationsiNGL increased net genomic loadpCNL positive copy number loadhetMNA heterogeneous MYCN-amplificationlcsh:RC254-282Polymorphism Single NucleotideGenomic InstabilityUHR ultra-high-riskOS overall survivalNet genomic load03 medical and health sciencesSCA segmental chromosomal aberrationInternal medicineNeuroblastomamedicineHumansNGL net genomic loadGenetic Predisposition to DiseaseGenomic imbalanceGenetic Association StudiesEFS event-free survivalProportional Hazards ModelsChromosome AberrationsPloidieshomMNA homogeneous MYCN-amplificationProportional hazards modelbusiness.industryGene AmplificationGenetic Variationmedicine.diseasePatient Outcome AssessmentCopy number aberration burden030104 developmental biologybusinessNeoplasia
researchProduct

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG …

2017

Background Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non…

MaleARDSdemographyeconomicmedicine.medical_treatmentTerapéuticaair conditioningComorbidityintensive care unitdeveloped country0302 clinical medicineneuromuscular blockingmiddle agedacute myocardial-infarctionmiddle income countryProspective StudiesGeography Medicalcritically-ill patientsadultagedpriority journalrisk factorIncomegeographic-variationDeveloped countryhospitalizationprospective studyHumanPulmonary and Respiratory MedicineDeveloped Countriemedicine.medical_specialtyDeveloping countryArticle/dk/atira/pure/subjectarea/asjc/2700/274003 medical and health sciencesSíndrome respiratorio agudo graveunitsMedicalHumansIntensive care medicineDeveloping CountriesAgedhigh income countryRespiratory Distress Syndrome Adultnoninvasive ventilationAparato respiratoriomedicine.diseasemortalitymajor clinical studyProspective Studiearterial oxygen tension030228 respiratory systemARDSObservational studySociologíahealth care deliverygeographyintensive-careRisk FactorsEpidemiologyProspective cohort studyRespiratory Distress Syndromepartial pressureartificial ventilationSociología médicaMiddle Agedadult respiratory distress syndromeAged; Comorbidity; Delivery of Health Care; Developed Countries; Developing Countries; Europe; Female; Geography Medical; Humans; Income; Intensive Care Units; Male; Middle Aged; Patient Outcome Assessment; Prospective Studies; Respiratory Distress Syndrome Adult; Risk Factors; Pulmonary and Respiratory MedicineEuropeIntensive Care UnitsfemaleincomeFemaleEnfermedadinjurycohort analysigross national incomesurvivalNOmedical geographyDeveloping Countrielength of staymedicinecontrolled studyoutcome assessmentbreast-cancerMechanical ventilationdiseasebusiness.industryDeveloped Countriespatient caredeveloping country030208 emergency & critical care medicinestatistics and numerical data AgedComorbiditywinterACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GEOGRAPHIC-VARIATION; INTENSIVE-CARE; BREAST-CANCER; MORTALITY; DISEASE; INJURY; UNITS; HOSPITALIZATIONPatient Outcome AssessmentEmergency medicineprone positiontreatment outcomebusinessDelivery of Health Care
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

2021

This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models wer…

MaleCOVID-19 COVIDSURG COVIDSURG CANCEROutcome AssessmentIMPACTSettore MED/18 - CHIRURGIA GENERALEBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Surgery.surgeryCancer surgeryNeoplasms/classificationBIOMEDICINA I ZDRAVSTVO. Javno zdravstvo i zdravstvena zaštita.Surgical oncologyNeoplasmsAcute careCOVID-19 - epidemiologyOutcome Assessment Health CareMedicine and Health Sciences80 and overGlobal healthtimingProspective StudiesUK610 Medicine & healthProspective cohort studyCOVID-19/epidemiologyCOVIDAged 80 and overBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology.BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Kirurgija.Hazard ratioArticlesMiddle AgedOncologyAdult; Aged; Aged 80 and over; Communicable Disease Control; COVID-19; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Proportional Hazards Models; Prospective Studies; SARS-CoV-2; Time-to-Treatment; Withholding Treatment/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalecancer surgeryCovid-19Life Sciences & BiomedicineMENTAL-HEALTHmental healthCohort studyHumanAdultmedicine.medical_specialtydelay3122 CancersCOVID-19 - prevention and control610 Medicine & healthCOVIDSurg CollaborativeNOTime-to-TreatmentSDG 3 - Good Health and Well-beingLockdownmedicineHumanscancer1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryLS7_4Proportional Hazards ModelsAgedScience & Technologybusiness.industrySARS-CoV-2Public healthGeneral surgeryBIOMEDICINE AND HEALTHCARE. Public Health and Health Care.COVID-193126 Surgery anesthesiology intensive care radiologyHealth CareCommunicable Disease Control/legislation & jurisprudenceProspective StudieWithholding TreatmentCOVID-19; delay; SARS-CoV-2; surgery; timing; cancer surgery;COVID-19 ; lockdowns ; cancer surgeryCommunicable Disease ControlBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija.Proportional Hazards ModelNeoplasmbusiness
researchProduct

Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

2020

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a …

MaleCancer ResearchOutcome AssessmentInternational CooperationSettore MED/18 - CHIRURGIA GENERALESettore MED/19 - Chirurgia Plastica030230 surgeryAged; Aged 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Postoperative Complications; SARS-CoV-2Cohort Studies0302 clinical medicineOperating theaterPostoperative Complicationscohort studiesNeoplasmsHealth caremiddle agedOutcome Assessment Health Care80 and overMedicineLungCancerCOVID-19/epidemiologyAged 80 and overOUTCOMESManchester Cancer Research CentrePulmonary ComplicationORIGINAL REPORTSMiddle AgedagedOncologyElective Surgical Procedures030220 oncology & carcinogenesisPneumonia & InfluenzaFemalePatient SafetyElective Surgical ProcedureLife Sciences & Biomedicine6.4 SurgeryCohort studyHumanmedicine.medical_specialtyelective surgical procedures/methodsLogistic ModelCritical CareAged; Aged; 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment; Health Care; Postoperative Complications; SARS-CoV-2Clinical SciencesOncology and CarcinogenesisEpidemic[SDV.CAN]Life Sciences [q-bio]/Cancer-.cancer surgery ; COVID-19 ; SARS-CoV-2 pandemicepidemicsCOVIDSurg CollaborativeNOoutcome assessment health care/methods03 medical and health sciencesmaleSettore MED/28 - Malattie OdontostomatologicheClinical ResearchHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryEpidemicsElective Cancer Surgery in SARS-CoV-2 Elective Cancer Surgery in COVID-19 covid 19 sars-cov-2AgedScience & TechnologyElective Surgical Procedurebusiness.industrySARS-CoV-2PreventionResearchInstitutes_Networks_Beacons/mcrcEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical SciencesPneumoniaOdds ratiomedicine.diseaseHealth CarePneumoniaGood Health and Well Beingneoplasms/surgeryLogistic Modelscritical care/methodsEmergency medicinepostoperative complications/prevention & controlNeoplasmPostoperative ComplicationCohort Studiebusinessaged 80 and overSARS-CoV-2/physiologylogistic models
researchProduct

Quality of life in patients with bladder cancer undergoing ileal conduit: A comparison of women versus men

2018

Background/Aim: Studies comparing health-related quality of life (HR-QoL) between patients who underwent radical cystectomy (RC) and those who underwent a different form of urinary diversion has not reached yet univocal and reliable conclusions. The aim of our study was to evaluate bladder-specific long-term HR-QoL after radical cystectomy and ileal conduit. Patients and Methods: A multicenter study was carried out on 145 consecutive patients (112 males and 33 females) undergoing RC and ileal conduit (IC). HR-QoL assessment was conducted using Italian versions of European Organisation for Research and Treatment of Cancer QLQ-C30 and EORTC BLM-30 questionnaires. Results: Our data showed that…

MaleGenetics and Molecular Biology (all)Cancer Researchmedicine.medical_treatment030232 urology & nephrologySex FactorUrinary DiversionBiochemistrySettore MED/24 - UrologiaBladder cancer; ileal conduit; quality of life; Orthotopic neobladder0302 clinical medicineQuality of lifeSurveys and QuestionnairesOutcome Assessment Health CareOrthotopic neobladderSurveys and QuestionnaireUrinary bladderSettore MED/24 - UROLOGIABladder cancerMiddle AgedhumanitiesBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Biochemistry Genetics and Molecular Biology (all); Pharmacologymedicine.anatomical_structureIleal conduit030220 oncology & carcinogenesisUrinary Bladder NeoplasmFemaleResearch ArticleHumanQuality of lifemedicine.medical_specialtyBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Aged; Female; Humans; Male; Middle Aged; Outcome Assessment (Health Care); Sex Factors; Surveys and Questionnaires; Urinary Bladder; Urinary Bladder Neoplasms; Urinary Diversion; Quality of Life; Biochemistry Genetics and Molecular Biology (all); PharmacologyUrinary BladderGeneral Biochemistry Genetics and Molecular BiologyCystectomy03 medical and health sciencesOutcome Assessment (Health Care)Sex FactorsInternal medicinemedicineHumansIn patientAgedPharmacologyBladder cancerBiochemistry Genetics and Molecular Biology (all)business.industryUrinary diversionCancermedicine.diseaseRadical cystectomyUrinary Bladder NeoplasmsBladder cancer; ileal conduit; orthotopic neobladder; quality of life; radical cystectomybusinessSexual function
researchProduct